ModernaTX mRNA Vaccine Patent, Lipid Nanoparticles, Apr 2026
Summary
USPTO published patent application US20260108595A1 assigned to ModernaTX, Inc., filed December 5, 2025 with Application No. 19410723, covering mRNA betacoronavirus vaccines formulated in lipid nanoparticles. Inventors are Giuseppe Ciarametta and Sunny Himansu. The published application is now publicly available in the USPTO database, establishing prior art and pending IP rights for the disclosed RNA vaccine technology.
“The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published patent application US20260108595A1 for ModernaTX, Inc. disclosing mRNA vaccines against betacoronaviruses formulated in lipid nanoparticles. The application claims specific RNA vaccine compositions and methods of using them.
For parties developing competing mRNA vaccine technologies or lipid nanoparticle delivery systems, this published application establishes prior art as of its December 5, 2025 filing date. Freedom-to-operate analyses should incorporate this document for any overlapping claims in the A61K 39/12 and C07K 16/10 CPC classifications.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BETACORONAVIRUS mRNA VACCINES
Application US20260108595A1 Kind: A1 Apr 23, 2026
Assignee
ModernaTX, Inc.
Inventors
Giuseppe Ciaramella, Sunny Himansu
Abstract
The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
CPC Classifications
A61K 39/12 A61K 39/155 A61K 39/215 A61P 11/00 A61P 31/14 C07K 16/10 C07K 16/102 C07K 16/11 A61K 2039/53 A61K 2039/55511 A61K 2039/55555 A61K 2039/6018 A61K 2039/70 C07K 2317/76 C12N 2760/18034 C12N 2760/18334 C12N 2760/18434 C12N 2760/18534 C12N 2760/18634 C12N 2770/20034 Y02A 50/30
Filing Date
2025-12-05
Application No.
19410723
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.